Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

18 Mar 2019

1509.10

-1.88%

CIPLA LTD

Hold: Cipla Ltd.

Target

Geojit BNP Paribas

Cipla reported mere 2% YoY growth in revenue in Q3FY19 as strong 31% YoY growth in North America business (contributing 21% to revenue) was offset by weak India revenue (down 1% YoY), which contributes ~40% of Cipla's revenue. Further, revenue from Cipla SAGA (South Africa, Sub-Saharan Africa and Cipla Global Access) business which is largely tender based, declined by 11% YoY in Q3FY19 impacted by certain one-time low-margin sales both for South Africa and CGA tender business, leading to inventory liquidation. However, South Africa private market continued its strong trajectory growing at 4x the market at 9.1%. Revenue from Europe business grew by 11% YoY in Q3FY19 on the back of expansion in respiratory franchise. Decline in India revenue was primarily due to high base last year on account of...

Cipla Ltd.'s price crossed below 100Day SMA today

Cipla Ltd.

07 Mar 2019

1509.10

-1.88%

Cipla Ltd. - Initiating Coverage - 07 March 2019

Results Update: Cipla Ltd.

Way2Wealth

Way2Wealth Brokers Pvt. Ltd. (CIN U67120KA2000PTC027628) SEBI Rgn. No. : INH200002739 No. 14, Frontline Granduer, Walton Road, Bangalore-560001; Website: www.way2wealth.com Email: research@way2wealth.com...

Cipla Ltd.'s price crossed below 100Day SMA today

Cipla Ltd.

06 Mar 2019

1509.10

-1.88%

First Light: Weekly Eco Wrap, Gujarat State Petronet

Buy: Cipla Ltd.

BOB Capital Markets Ltd.

Economic data in the week pointed to a dip in global growth momentum. Manufacturing activity in both US and China decelerated. Trade talks between US and China and a positive surprise in US growth drove global equity markets higher, especially China. Even as Fed indicated to be patient and crude prices edged lower, global yields went up. Indian yields were lower as geo-political tensions eased and GDP growth slowed to a six-quarter low of 6.6%. This may...

Cipla Ltd. is trading above its 200 day SMA of 1494.7

Cipla Ltd.

20 Feb 2019

1509.10

-1.88%

Cipla

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

The South African government has announced results of three-year (2019-21) ARV tenders for TEE (Tenofovir, Emtricitabine and Efavirenz) and TLD (Tenofovir Lamivudine, Dolutegravir) 3-in-1 combinations effective Jul'19. While full details are yet to emerge, our interaction with Cipla suggests an allocation of ~US$ 30mn-35mn in tender value (10% share of the US$ 1bn tender) on an annualised basis, assuming a high double-digit price discount. The share represents a ~42% decrease from the previous tender in 2014....

Cipla Ltd. is trading below its 30 day SMA of 1564.3

Cipla Ltd.

12 Feb 2019

1509.10

-1.88%

Cipla

Results Update: Cipla Ltd.

SMC online

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

07 Feb 2019

1509.10

-1.88%

Cipla (3QFY19): US at a sweet spot. Maintain BUY

Buy: Cipla Ltd.

HDFC Securities

The stock is trading at 24.6/18.3x FY20/21E EPS, a ~15% discount to its historical average. Maintain BUY with a TP of Rs 605 (22x Dec-20E EPS). Ciplas reported an in-line quarter with revenue at Rs 40.1bn, up 2% YoY/ flat QoQ. EBITDA stood at Rs 7.1bn with margin at 17.7%, down 326bps YoY due to continued API cost inflation and falling prices in the tender business. PAT at Rs 3.3bn was down 17/12% YoY/QoQ (in-line). With a ~9% QoQ jump in US revenues (US$ 118mn), Cipla will most likely overshoot its guidance of US$ 125mn US revenues in 4Q.

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

07 Feb 2019

1509.10

-1.88%

Cipla

Hold: Cipla Ltd.

Target

ICICI Securities Limited

Q3FY19 results were in line on the operational front but net profit was higher than I-direct estimates due to higher other income. Revenues grew 2.4% YoY to | 4007.5 crore (I-direct estimate: | 4081.6 crore). A 31% YoY growth in the US to | 849 crore (I-direct estimate: | 781.2 crore) was largely offset by 1% decline in domestic market to | 1585 crore (I-direct estimate: | 1681.1 crore) EBITDA margins contracted 326 bps YoY to 17.7% (I-direct estimate: 17.0%) due to lower gross margins and higher employee cost....

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

04 Jan 2019

1509.10

-1.88%

Cipla

Buy: Cipla Ltd.

BOB Capital Markets Ltd.

US ramp-up progressing well H2 muted but largely priced in We met the Cipla management who reiterated their focus on building US operating leverage and confidence in achieving 18-19% EBITDA margins in the business for FY19 despite tender contract headwinds. Tender business US funding squeeze, price pressure to weigh on growth: Cipla expects a sharp cut in Global Access (GA) revenues in FY19 to US$ 60mn70mn (US$ 110mn in FY18). The South Africa (SA) tender business which forms ~40% of SA revenue should see allocation for the three-year tender cycle kicking in by Apr'19 (bidding process underway). Management expects H2FY19...

Cipla Ltd.'s price crossed below 100Day SMA today

Cipla Ltd.

26 Dec 2018

1509.10

-1.88%

Cipla (Update): Negatives priced-in. Upgrade to BUY

Buy: Cipla Ltd.

Recommendation

HDFC Securities

Upgrade to BUY with a TP of Rs 605 (22x Dec-20E EPS). The recently diagnosed issues related to supply constraints in one of the sterile plants, US sanctions on Iran, war in Yemen, falling prices in the tender business and higher inflation in APIs are likely to persist over the next 2-3 quarters.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

09 Nov 2018

1509.10

-1.88%

Cipla

Results Update: Cipla Ltd.

SMC online

Cipla Limited's profit misses analysts' estimates in the July-September period, even as its operational performance fell short of expectations. Net sales declined 2 percent to Rs 4,011 crore year-on-year, the operating income, or earnings before interest, tax, depreciation, and amortization, fell 12 percent over the last year to Rs 702 crore. The operating margin contracted to 17.5 percent during the period from 19.7 percent a year ago. It has reported a fall of 11 percent (year-on-year) in its net profit for the September...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Is Cipla Ltd. worth buying?

623 Votes:

Buy 75.76%

Sell 13.96%

Hold 10.27%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf